Drug name - Dymista
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(8 months from now) | |
| US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(8 months from now) | |
| US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(10 months from now) | |
|
US9259428
(Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Dec, 2023
(1 year, 2 months from now) | |
|
US8163723
(Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(1 year, 4 months from now) | |
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(3 years from now) | |
|
US8168620
(Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(3 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Treatment: Treatment of seasonal allergic rhinitis; Treatment of seasonal allergic rhinitis; treatment of allergic rhinitis, including seasonal allergic rhinitis; allergic rhinitis; treatment of symptoms of seasonal allergic rhinitis; relief of symptoms associated with seasonal allergic rhinitis
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.137MG/SPRAY;0.05MG/SPRAY | SPRAY, METERED;NASAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.